Bullish Outlook on Zura Bio Limited (ZURA) Amid Tibulizumab Phase 2 Clinical Trial Progress

With strong three-month performance and significant upside potential, Zura Bio Limited (NASDAQ:ZURA) secures a spot on our list of the 12 hot penny stocks to invest in right now. Bullish Outlook on Zura Bio Limited (ZURA) Amid Tibulizumab Phase 2 Clinical Trial Progress Copyright: zneb076 / 123RF Stock Photo On November 13, 2025, Guggenheim reiterated its “Buy” rating on Zura Bio Limited (NASDAQ:ZURA) with a $15 price target. The reaffirmed outlook came as Zura Bio Limited (NASDAQ:ZURA) reported its re ...